WALTHAM, Mass.–(BUSINESS WIRE)–Mar 21, 2022–
“We proceed to speculate strategically in each world capability and superior capabilities that simplify the provision chain and speed up the tempo of pharmaceutical growth,” mentioned Leon Wyszkowski, president of economic operations, pharma companies, Thermo Fisher Scientific. “Our focus has been on growing built-in capabilities that join your entire worth chain — from early growth and scale-up to industrial manufacturing — in addition to leveraging new transformative digital applied sciences to assist pace the supply of breakthrough medicines and therapies to sufferers.”
Simplifying the Provide Chain for Cell and Gene Therapies
The demand for cell and gene therapies is fueling exponential progress. This yr, Thermo Fisher will open one of many largest viral vector websites in North America. The almost 300,000-square-foot facility in Plainville, Mass., will lengthen the corporate’s world industrial viral vector community to 6 websites.
Later this yr, Thermo Fisher will increase its cell remedy community with the addition of a new cell remedy growth and cGMP manufacturing middle on the College of California San Francisco, Mission Bay campus. The location will present prospects with built-in options to scale back value and speed up adoption of cell therapies.
To deal with the necessity for commercial-quality plasmid DNA, Thermo Fisher opened its new cGMP Plasmid manufacturing facility in Carlsbad, Calif., to assist medical and industrial wants for prime quality uncooked materials and drug substance growth for cell and gene therapies and vaccines.
Moreover, the corporate can also be launching new mRNA synthesis capabilities to provide drug substance for vaccines and therapies
Enabling Early-Stage Course of Growth
Thermo Fisher has added new capabilities to assist early-stage growth, shorten pre-clinical examine timelines and speed up commercialization. New translational sciences labs will open in San Diego, Calif., and Alachua, Fla., to assist cell and gene remedy growth for the pharmaceutical innovators transitioning drug candidates into pre-clinical research.
As well as, new Fast to Clinic built-in companies join companies throughout the worth chain and create workflows to permit speedy course of growth and diminished cycle instances. New Fast to Look after superior therapies affords an end-to-end, customizable resolution that integrates drug growth and medical companies throughout the cell and gene remedy worth chain to hurry entry to breakthrough therapies. New Patheon Industrial Packaging Companies for Cell and Gene Therapies mix GMP storage, serialization, ultracold and cryogenic packaging, and world distribution to fulfill specialised wants to make sure CGT provide chain integrity.
Increasing Steriles, Product Growth & Biologics Capabilities
The corporate has expanded its capabilities to assist the accelerated demand for world steriles and biologics manufacturing. Over the past two years, Thermo Fisher has added 13 new aseptic filling strains and expanded its product growth companies throughout its world community.
Thermo Fisher is doubling biologics manufacturing capability at its St. Louis, Mo., website to assist manufacturing progress from 2KL to 5KL. As well as, the corporate assumed operational duty of its new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, which options extremely versatile bioproduction applied sciences and supplies a pathway from growth to large-scale manufacturing.
Later this yr, the corporate will increase into Asia-Pacific. In Hangzhou, China, a brand new manufacturing facility would be the first to supply built-in biologics drug substance and sterile drug product capabilities. In Singapore, a brand new sterile manufacturing facility will provide large-scale capability and high-speed filling.
Digital Transformation of the Provide Chain
Thermo Fisher is leveraging new digital applied sciences throughout its pharma companies community to create manufacturing efficiencies and streamlined processes. New capabilities embrace implementation of Pharma 4.0 to harmonize and combine knowledge and drive digital transformation inside all phases of drug growth and manufacturing. As well as, the corporate’s new mysupply digital provide chain platform supplies prospects with visibility and collaboration throughout their full product lifecycle together with day by day order administration, batch monitoring and month-to-month forecasting.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world chief in serving science, with annual income of roughly $40 billion. Our Mission is to allow our prospects to make the world more healthy, cleaner and safer. Whether or not our prospects are accelerating life sciences analysis, fixing advanced analytical challenges, rising productiveness of their laboratories, bettering affected person well being via diagnostics or the event and manufacture of life-changing therapies, we’re right here to assist them. Our world crew delivers an unequalled mixture of modern applied sciences, buying comfort and pharmaceutical companies via our industry-leading manufacturers, together with Thermo Scientific, Utilized Biosystems, Invitrogen, Fisher Scientific, Unity Lab Companies, Patheon and PPD. For extra info, please go to www.thermofisher.com.
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS
INDUSTRY KEYWORD: RESEARCH MEDICAL SUPPLIES INFECTIOUS DISEASES GENETICS CLINICAL TRIALS BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE
Copyright Enterprise Wire 2022.
PUB: 03/21/2022 04:05 PM/DISC: 03/21/2022 04:06 PM
Copyright Enterprise Wire 2022.